Blood News and Research

RSS

PEPFAR's second five-year phase will strengthen healthcare systems

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, has praised the recent announcement that the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) will increase its emphasis over the next five years on strengthening health systems in developing countries.

From BD (Becton, Dickinson and Company) 9 Jan 2010

Biomarker may enable personalized GVHD treatment for bone marrow transplant patients

University of Michigan researchers have identified the first biomarker of graft-versus-host disease of the skin. The discovery makes possible a simple blood test that should solve a treatment dilemma facing doctors with patients who frequently develop rashes after bone marrow transplants.

9 Jan 2010

Centron receives agency of record assignments for FRAGMIN and GLIADEL Wafer medicines

HealthSTAR's Centron, a medical communications company, is pleased to announce that they have been awarded agency of record assignments for FRAGMIN® and GLIADEL® Wafer from Eisai Inc.

9 Jan 2010

FDA grants unconditional approval for World Heart's Levacor VAD BTT study

World Heart Corporation, a developer of mechanical circulatory systems, announced today that it has received unconditional approval from the U.S. Food and Drug Administration ("FDA") for the bridge-to-transplant ("BTT") study of the Levacor Ventricular Assist Device ("VAD"). Study enrollment will encompass 160 subjects, a reduction from the approximately 200 subjects of the original statistical plan. As previously announced, the BTT study will begin initially at ten clinical sites.

8 Jan 2010

Japanese MHLW approves Abbott's XIENCE V Everolimus Eluting Coronary Stent System

Abbott announced today that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved its XIENCE V® Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease.

8 Jan 2010

Specialized software provides 3D images of individual patients' livers

Odysseus has developed systems to construct 3D images of individual patients' livers, with their tumours or other pathologies, from MRI or CT-scans. The reconstructions can be transmitted to external experts in any location, for consultation in real time just before surgery.

8 Jan 2010

Critically ill children with flu-like symptoms should be treated preemptively with antiviral medications

Lessons learned from the first 13 children at Johns Hopkins Children's Center to become critically ill from the H1N1 virus show that although all patients survived, serious complications developed quickly, unpredictably, with great variations from patient to patient and with serious need for vigilant monitoring and quick treatment adjustments.

8 Jan 2010

Chinese researchers become the world's fifth most prolific contributors to regenerative medicine

Chinese researchers have become the world's fifth most prolific contributors to peer-reviewed scientific literature on clock-reversing regenerative medicine even as a skeptical international research community condemns the practice of Chinese clinics administering unproven stem cell therapies to domestic and foreign patients.

8 Jan 2010

A.D.A.M. announces new online education product for K-12 market

A.D.A.M., Inc., a leading provider of consumer health information, benefits technology solutions and interactive education resources, today announced the availability of A.D.A.M. Inside Out, its newest online education product for the K-12 education market. A.D.A.M. Inside Out offers a unique opportunity for K-12 students to learn about the human body.

8 Jan 2010

King Center to host second annual 'Health and Wellness Forum'

The King Center announced that it will officially launch the 2010 MLK Birthday Observance on Saturday, Jan. 9, 2010 by hosting and co-sponsoring its second annual “Health and Wellness Forum.” It is being co-sponsored by a $50,000 grant from Aetna, which also funded last year’s inaugural program.

8 Jan 2010

Scientists identify gene underlying a disease that causes temporary paralysis of skeletal muscle

Scientists have identified a gene underlying a disease that causes temporary paralysis of skeletal muscle. The finding, they say, illustrates how investigations of rare genetic diseases can drive insights into more common ones.

8 Jan 2010

MicroCHIPS raises $16.5 million to fund for diabetes and osteoporosis programs

MicroCHIPS, Inc., a developer of intelligent implant systems, has raised $16.5 million to fund its lead programs in diabetes and osteoporosis. Current investors Polaris Venture Partners, Novartis Venture Fund, Flybridge Capital Partners, Medtronic, Saints Capital, Intersouth Partners, Care Capital and CSK Venture Capital were joined by new investor InterWest Partners.

8 Jan 2010

Emerging Healthcare Solutions seeks business opportunities with new, patented T-Guide Platelet Function Analyzer

Emerging Healthcare Solutions, Inc. under their exclusive option agreement with Thrombovision, has begun due diligence to aggressively seek the establishment of business opportunities with the new patented T-Guide Platelet Function Analyzer.

8 Jan 2010

Researchers devise method to pinpoint key genetic variations under positive natural selection that may impact human health

Fossils may provide tantalizing clues to human history but they also lack some vital information, such as revealing which pieces of human DNA have been favored by evolution because they confer beneficial traits - resistance to infection or the ability to digest milk, for example. These signs can only be revealed through genetic studies of modern humans and other related species, though the task has proven difficult.

8 Jan 2010

Preliminary studies show cancer vaccine may reduce tumor cells in CML patients

Johns Hopkins Kimmel Cancer Center researchers say preliminary studies show that a vaccine made with leukemia cells may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Imatinib mesylate (Gleevec).

8 Jan 2010

Center for Attention Deficit and Learning Disorders adds HEG to its list of treatment options

The Center for Attention Deficit and Learning Disorders announces today that it has added Hemoencephalography (HEG) to its list of treatment options for patients with ADD/ADHD, learning disabilities, mood disorders and other conditions.

8 Jan 2010

Non-insulin-dependent patients with type 2 diabetes do not benefit from glucose self-monitoring

Contrary to the widely-held belief, there is no proof that non-insulin-dependent patients with type 2 diabetes benefit from glucose self-monitoring. Moreover, it remains unclear whether an additional benefit is displayed by the blood test compared to the urine test or vice versa, in other words, whether one or other of the tests might offer an advantage to patients.

8 Jan 2010

Majority of long-term cancer survivors do not have access to personalized care services

An increasing number of people are surviving cancer, but many do not receive the services and support they need in the long term, Macmillan Cancer Support has said.

8 Jan 2010

National survey reveals many Canadians understand risk of colon cancer, but are not taking action

A new national survey reveals that while almost all Canadians understand the importance of getting checked for colon cancer, most have not had a screening test and are confused about how and when it should happen.

8 Jan 2010

Laureate Pharma and Iconic Therapeutics complete manufacturing hI-con1 recombinant Fc-Factor VII fusion protein

Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company specializing in the development and GMP manufacture of monoclonal antibodies, fusion proteins and other therapeutic protein products, and Iconic Therapeutics, a company focused on the development of treatments for wet adult macular degeneration (wet AMD) and other ophthalmic diseases, today announced the completion of the manufacture of the first GMP lot of hI-con1(TM) recombinant Fc-Factor VII fusion protein.

8 Jan 2010

Blood News and Research

PEPFAR's second five-year phase will strengthen healthcare systems

Biomarker may enable personalized GVHD treatment for bone marrow transplant patients

Centron receives agency of record assignments for FRAGMIN and GLIADEL Wafer medicines

FDA grants unconditional approval for World Heart's Levacor VAD BTT study

Japanese MHLW approves Abbott's XIENCE V Everolimus Eluting Coronary Stent System

Specialized software provides 3D images of individual patients' livers

Critically ill children with flu-like symptoms should be treated preemptively with antiviral medications

Chinese researchers become the world's fifth most prolific contributors to regenerative medicine

A.D.A.M. announces new online education product for K-12 market

King Center to host second annual 'Health and Wellness Forum'

Scientists identify gene underlying a disease that causes temporary paralysis of skeletal muscle

MicroCHIPS raises $16.5 million to fund for diabetes and osteoporosis programs

Emerging Healthcare Solutions seeks business opportunities with new, patented T-Guide Platelet Function Analyzer

Researchers devise method to pinpoint key genetic variations under positive natural selection that may impact human health

Preliminary studies show cancer vaccine may reduce tumor cells in CML patients

Center for Attention Deficit and Learning Disorders adds HEG to its list of treatment options

Non-insulin-dependent patients with type 2 diabetes do not benefit from glucose self-monitoring

Majority of long-term cancer survivors do not have access to personalized care services

National survey reveals many Canadians understand risk of colon cancer, but are not taking action

Laureate Pharma and Iconic Therapeutics complete manufacturing hI-con1 recombinant Fc-Factor VII fusion protein

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News